Skip to main content
AmigoFish

STIFEL 2026: Compugen has a trial in ovarian cancer for its PVRIG scheduled to read out in the early part of 2027 - later that year brings the start of Astra's big readouts with the TIGIT bispecific

From BiotechTV - News · · 10 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

CEO Eran Ophir defines what would be a success in the ovarian trial and possible next steps if successful. Plus, TIGIT, Gilead's work on IL18, and looking for new T-cell engager targets.

Back to BiotechTV - News · Report a problem